Predictors of plasma lipoprotein(a) concentration in the West of Scotland Coronary Prevention Study cohort

Atherosclerosis

Volumn 143, Issue 2, 1999, Pages 445-450

  Gaw, Allan ^a   Docherty, Gillian ^b   Ann Brown, E ^b   Ford, Ian ^b  

^a 4th Fl Qu Elizabeth Bldg Roy I ^*  (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Apolipoprotein(a); Lipoprotein(a); Phenotyping; Polymorphism

Indexed keywords

APOLIPOPROTEIN A; LIPOPROTEIN A;

ADULT; AGED; ALLELE; ARTICLE; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SCREENING; UNITED KINGDOM;

AGE DISTRIBUTION; APOLIPOPROTEINS A; COHORT STUDIES; CORONARY DISEASE; HUMANS; INCIDENCE; LIPOPROTEIN(A); MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SAMPLING STUDIES; SCOTLAND; SENSITIVITY AND SPECIFICITY;

EID: 0032947472     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(98)00305-0     Document Type: Article

References (34)

1. Cremer P., Nagel D., Labrot B. et al. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS). Eur. J. Clin. Invest. 24:1994;444.
2. Bostom A.G., Cupples L.A., Jenner J.L. et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger: a prospective study. J. Am. Med. Assoc. 276:1996;544.
3. Utermann G. Lipoprotein(a). In: Scriver CR, Beaudet A, Sly WS, Valle D, editors. The Metabolic Basis of Inherited Disease. New York: McGraw Hill, 1995:1887.
4. Gaw A., Hobbs H.H. Molecular genetics of lipoprotein(a): new pieces to the puzzle. Curr. Opin. Lipidol. 5:1994;149.
5. Utermann G., Menzel H.J., Kraft H.G., Duba H.C., Kemmler H.G., Seitz C. Lp(a) glycoprotein phenotypes: Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J. Clin. Invest. 80:1987;458.
6. Lackner C., Boerwinkle E., Leffert C.C., Rahmig T., Hobbs H.H. Molecular basis of apolipoprotein(a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. J. Clin. Invest. 87:1991;2077.
7. Boerwinkle E., Leffert C.C., Lin J., Lackner C., Chiesa G., Hobbs H.H. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J. Clin. Invest. 90:1992;52.
8. Boerwinkle E., Menzel H.G., Kraft H.G., Utermann G. Genetics of the quantitative Lp(a) lipoprotein trait. III: contribution of Lp(a) glycoprotein phenotypes to normal lipid variation. Hum. Genet. 82:1989;73.
9. Gaubatz J.W., Ghanem K.I., Guevara J. Jr., Nava M.L., Patsch W., Morrisett J.D. Polymorphic forms of human apolipoprotein(a): Inheritance and relationship of their molecular weights to plasma levels of lipoprotein(a). J. Lipid Res. 31:1990;603.
10. Gaw A, Brown EA, Ford I. On the impact of apo(a) length polymorphism and the control of plasma Lp(a) concentrations: evidence for a threshold effect. Arterioscler Thromb Vasc Biol. 18:1998;1870-1876.
11. Sandkamp M., Funke H., Schulte H., Köhler E., Assmann G. Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age. Clin. Chem. 36:1990;20.
12. Albers J.J., Hazzard W.R. Immunochemical quantification of human plasma Lp(a) lipoprotein. Lipids. 9:1974;15.
13. Heinrich J., Sandkamp M., Kokott R., Schulte H., Assmann G. Relationship of lipoprotein(a) to variables of coagulation and fibrinolysis in a healthy population. Clin. Chem. 37:1991;1950.
14. Jenner J.L., Ordovas J.M., Lamon-Fava S. et al. Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels: the Framingham Offspring Study. Circulation. 87:1993;1135.
15. Sundell I.B., Nilsson T.K., Hallmans G., Hellsten G., Dahlen G.H. Interrelationships between plasma levels of plasminogen activator inhibitor, tissue plasminogen activator, lipoprotein(a), and established cardiovascular risk factors in a North Swedish population. Atherosclerosis. 80:1989;9.
16. Giavarina D., Dorizzi R., Giavarina M., Schiavon R. Age-related correlations between weight and lipoprotein(a) concentrations. Clin. Chem. 38:1992;1386.
17. Corsetti J.P., Sterry J.A., Sparks J.D., Sparks C.E., Weintraub M. Effect of weight loss on serum lipoprotein(a) concentrations in an obese population. Clin. Chem. 37:1991;1191.
18. Lobo R.A., Notelovitz M., Bernstein L., Khan F.Y., Ross R.K., Paul W.L. Lp(a) lipoprotein: relationship to cardiovascular disease risk factors, exercise, and estrogen. Am. J. Obstet. Gynecol. 166:1992;1182.
19. Mankowitz K., Seip R., Semenkovich C.F., Daugherty A., Schofeld G. Short-term interruption of training affects both fasting and post-prandial lipoproteins. Atherosclerosis. 95:1992;181.
20. Albers J.J., Adolphson J.L., Hazzard W.R. Radio-immunoassay of human plasma Lp(a) lipoprotein. J. Lipid Res. 18:1977;331.
21. Brown S.A., Morrisett J., Patsch J.R., Reeves R., Gotto A.M. Jr., Patsch W. Influence of short term dietary cholesterol and fat on human plasma Lp(a) and LDL levels. J. Lipid Res. 32:1991;1281.
22. Mensink R.P., Zock P.L., Katan M.B., Hornstra G. Effect of dietary cis and trans fatty acids on serum lipoprotein(a) levels in humans. J. Lipid Res. 33:1992;1493.
23. Nestel P., Noakes M., Belling B., Mcarthur R., Slifton P., Janus E., Abbey M. Plasma lipoprotein lipid and Lp(a) changes with substitution of elaidic acid for oleic acid in the diet. J. Lipid Res. 33:1992;1029.
24. Marth E., Cazzolato G., Bittolo Bon G., Avogaro P., Kostner G.M. Serum concentrations of Lp(a) and other lipoprotein parameters in heavy alcohol consumers. Ann. Nutr. Metab. 26:1982;56.
25. Boomsma D.I., Kaptein A., Kempen H.J.M., Gevers-Leuven J.A., Princen H.M.G. Lipoprotein(a): relation to other risk factors and genetic heritability. Results from a Dutch parent-twin study. Atherosclerosis. 99:1993;23.
26. Bartens W., Rader D.J., Talley G., Brewer H.B. Lipoprotein(a) in patients with hyperlipidaemia. Eur. J. Clin. Invest. 25:1995;647.
27. Boyer H., De Gennes J.L., Truffert J., Chatellier G., Dairou F., Bruckert E. Lp(a) levels in different types of dyslipidemia in the French population. Atherosclerosis. 85:1990;61.
28. WOSCOPS Study Group. Screening experience and baseline characteristics in the West of Scotland Study. Am J Cardiol 1995;76:485.
29. Shepherd J.S.M., Cobbe I., Ford C.G. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Engl. J. Med. 333:1995;1301.
30. Jauhiainen M., Koskinen P., Ehnholm C., Frick M.H., Mänttäri M., Manninen V., Huttunen J.K. Lipoprotein(a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis. 89:1991;59.
31. Lipid Research Clinics Program. Lipid and Lipoprotein Analysis: Manual of Laboratory Operations (Publication NIH/75-628). Washington DC: Department of Health, Education and Welfare, 1982.
32. Kamboh M.I., Ferrell R.E., Kottke B.A. Expressed hypervariable polymorphism of apolipoprotein(a). Am. J. Hum. Genet. 49:1991;1063.
33. Gaw A., Boerwinkle E., Cohen J.C., Hobbs H.H. Comparative analysis of the apo(a) gene, apo(a) glycoprotein, and plasma concentrations of Lp(a) in three ethnic groups. Evidence for no common 'null' allele at the apo(a) locus. J. Clin. Invest. 93:1994;2526.
34. Gaw A., Chiesa G. Characterization of commercial antibodies for use in high resolution apo(a) phenotyping by immunoblot analysis. Clin. Chim. Acta. 240:1995;75.